Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease

H. Lundbeck A/S today announced the initiation of a multi-centre,
placebo-controlled, fixed-dose study of Lu AE58054 as add-on to
donepezil in patients with moderate Alzheimer's disease. The clinical
phase II study is planned to enrol approximately 270 patients. The
purpose of this study is to investigate if Lu AE58054 after 24 weeks
improves cognition and functional outcomes in patients with moderate
Alzheimer's disease that are already in treatment with donepezil.

"Alzheimer's disease is one of the most complex and challenging areas
of research and development, but also an area with huge unmet medical
needs," says Executive Vice President Anders Gersel Pedersen, Head of
Drug Development at Lundbeck. "We are very pleased that Lundbeck can
continue to deliver projects that potentially can alter the course of
this debilitating neurological disease and radically change the lives
of patients."

About Lu AE58054
Lu AE58054 is a potent and selective 5-HT6-receptor antagonist. The
5-HT6-receptor is primarily found in areas of the brain involved in
cognition. A number of early trials have demonstrated that a
5-HT6-receptor antagonist could offer potential in the treatment of
disorders such as Alzheimer's disease and schizophrenia and in
November 2008 Lundbeck initiated a 12 week clinical phase II trial in
schizophrenia. The present study examines the possible benefit of Lu
AE58054 over a much longer period in Alzheimer's disease.

About Alzheimer's disease
Alzheimer's disease is a neurodegenerative disease characterised by
progressive cognitive impairment such as memory loss, reduced
perception ability and language disruptions, eventually preventing
the patient from taking care of him-/herself. Anxiety, confusion and
anger may occur in the later stages of the disease.

Alzheimer's disease affects 5% of the population over the age of 65
and more than 30% of those aged over 85. Today, about 60% of
Alzheimer's patients are diagnosed, and of these about 80% are
diagnosed with either moderate or severe Alzheimer's disease. It is
estimated that there are between 5-6 million people with dementia in
Europe. The total costs to society are estimated to amount to EUR 55
billion making dementia the most costly brain disorder[1]. The aging
population in Europe will make dementia an even bigger burden to
society in the years to come. Studies have shown that even relatively
small delays in disease progression will have huge impact on medical
costs.

Financial guidance
The content of this release will have no influence on the Lundbeck
Group's financial result for 2009.


Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Mads Kronborg
Director, IR & Communication Media Relations
+45 36 43 30 79              +45 36 43 28 51

Palle Holm Olesen            Kasper Riis
Head of Investor Relations   Media Relations
+45 36 43 24 26              +45 36 43 28 33

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improve the quality of
life for people suffering from central nervous system (CNS)
disorders. For this purpose Lundbeck is engaged in the research and
development, production, marketing and sale of pharmaceuticals across
the world, targeted at disorders like depression and anxiety,
schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,
and employs today over 5,500 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders.
In 2008, the company's revenue was DKK 11.3 billion (approximately
EUR 1.5 billion or USD 2.2 billion). For more information, please
visit www.lundbeck.com.

[1] Costs of Disorders of the Brain in Europe; European Journal of
Neurology; Volume 12, Supplement 1, June 2005